ABSTRACT
INTRODUCTION
Fine-needle aspirate samples from tumors can be manipulated with molecular biology protocols to help to reveal the molecular mechanisms of cancer (3, 8, 9) . In addition, they can be used to monitor the course of the disease and the tumor's response to treatment (2, 4, 10, 11, 13, 15, 16) .
For this study we have extracted RNA from fine-needle aspirate samples to use in conjunction with gene-dense cDNA expression microarrays (1) . The fine-needle aspirate samples used in this study were collected from breast cancer patients and were immediately added to RNAlater RNA Stabilization Reagent (Ambion, Austin, TX, USA) (7) . In general, the manufacturer's suggested protocol instructs the user to sediment the cells in the RNAlater by centrifugation and to discard the supernatant, treating only the cell pellet for RNA isolation. We reasoned that membrane lysis of some tumor cells would occur as a result of the shearing needle movement during the fine-needle aspirate sampling procedure, rinsing, mixing, and lysing of the cells during freeze-and-thaw as a cellular suspension in RNAlater. Here we separated the cell pellet and the supernatant and attempted to extract RNA from each fraction. RNA from each fraction was then amplified, labeled, and hybridized onto cDNA microarrays, comparing each fine-needle aspirate's cell pellet to its supernatant.
MATERIALS AND METHODS

RNA Isolation from Fine-Needle Aspirates
Tumor samples were obtained in a standard clinical manner by fine-needle aspirate using a 25-gauge needle attached to a 10-cm 3 syringe. A single ex vivo fine-needle aspirate sample was obtained from each of 11 breast cancer specimens immediately following surgical resection. The tumor samples were anonymous. Immediately upon collection, fine-needle aspirates within the needle hub were rinsed in 200 µL RNAlater. The time delay between devascularization and entry into RNAlater varied from 10 to 30 min. The tumor samples were kept at room temperature for 30 min and then stored at -80°C, usually for less than one month. RNA was isolated using the RNeasy ® Mini kit (Qiagen, Valencia, CA, USA). Tumor samples were thawed on ice, and cells were pelleted by centrifugation for 5 min at 9500× g in a refrigerated model Z 233 MK centrifuge (Hermle Labnet, Wehingen, Germany). The RNAlater solution was removed from the cell pellet and placed into a fresh, nuclease-free, 1.5-mL Eppendorf ® tube. Both the cell pellet and RNAlater supernatant were independently subjected to the RNA isolation procedure as separate samples, as described in the manufacturer's suggested protocol, except that each lysate was homogenized by passing it through a 28-gauge needle 10-20 times. RNA was eluted twice in 40 µL nuclease-free water (Invitrogen, Carlsbad, CA, USA) by centrifuging for 1 min at 20 000× g after applying the water directly to the membrane.
RNA Analysis and Quantitation
Each sample was analyzed with a spectrophotometer at 260 and 280 nm for RNA concentration and protein contamination and then evaluated for degradation and genomic DNA contamination on a 1% denaturing agarose gel containing 1× MOPS buffer and 2% formaldehyde. In addition, each sample was also loaded into an RNA LabChip ® and analyzed on the model 2100 Bioanalyzer using the RNA 6000 Nano Assay (Caliper Technologies, Mountain View, CA, USA).
Microarray Hybridization
Based on the RNA yield and quality for the cell pellet and supernatant portions, five fine-needle aspirates were chosen to be hybridized to a cDNA microarray containing 4800 features produced in-house. RNA samples were reverse-transcribed and made doublestranded using a second-strand synthesis protocol that was followed a single round of in vitro transcription with T7 RNA polymerase as previously described (12, 14, 17) . For each FNA sample chosen, the cell pellet's amplified RNA was labeled with Cy5 dCTP while the supernatant's amplified RNA was labeled with Cy3 dCTP. Labeled fractions from individual fine-needle aspirate samples were co-hybridized, and the slides were then scanned on an LS-IV laser scanner (Genomic Solutions, Ann Arbor, MI, USA). For each fine-needle aspirate sample, the results from the cell pellet were compared directly to those from the supernatant using the GeneSpring Version 4.1.5 software package (Silicon Genetics, Redwood City, CA, USA).
RESULT S
RNA was isolated from fine-needle aspirate samples from 11 breast cancers, first separating the cell pellet from the RNAlater supernatant and isolating RNA from each portion independently. Paired RNA samples were quantitated spectrophotometrically and analyzed for protein contamination. All samples yielded sufficient RNA to be detectable by spectrophotometer ( Table 1 ). On average, samples yielded a total of 3 µg total RNA with 53% of the total RNA coming from the cell pellet. The 260/280 ratios ranged from 1. RNA samples to be relatively free from significant protein contamination. Each RNA sample was evaluated for degradation by denaturing agarose gel electrophoresis. RNA that is not degraded should have two clear bands, representing the 28S and 18S rRNA species, with the larger 28S band appearing twice as bright as the 18S band. The sample should also be free of contaminating genomic DNA, which would appear on the gel as a band larger than the 28S rRNA band. Most of the RNA samples isolated from the fine-needle aspirate samples have detectable 28S and 18S rRNA bands, but they show some signs of degradation, possibly because of variable delay between surgical excision and ex vivo sample collection. The quality of RNA was the same in matched pairs of cell pellet and supernatant from the same tumor fineneedle aspirate sample (Figure 1 ). In addition, samples in Figure 1 , lanes 5, 6, and 8, show possible contamination with genomic DNA.
An aliquot from each RNA sample was also loaded on the model 2100 Bioanalyzer. The Bioanalyzer is an automated system that uses both microfluidics and gel electrophoresis technologies to enable analysis of DNA, RNA, and protein samples. The Bioanalyzer uses microelectrodes to electrophorese samples through capillary channels in the chip onto which the samples are loaded. As nucleic acid samples move through the gel matrix, they incorporate dye that the machine detects and displays as peaks. The software uses a ladder and internal markers to quantitate and size fragments in each sample. Using this technique, the Bioanalyzer system conducts a rapid, highly sensitive assay that has better resolution than denaturing gel electrophoresis.
For a Bioanalyzer run designated for RNA analysis, the software recognizes the peaks representing 28S and 18S rRNA, assigns empirical values for the area of each, and calculates the corresponding 28S/18S ratio for each sample. Ratios in the range of 1.5-2.5 indicate high-quality RNA that is free of degradation. The majority of the RNA samples from FNA showed detectable 28S and 18S rRNA peaks, but they also showed significant degradation ( Figure  2 and Table 1 ). A small number of samples actually had 28S/18S rRNA ratios of 0.0 because the software did not identify any peaks, perhaps because of underloading the sample on the chip.
Five FNA samples were chosen to be hybridized on cDNA microarrays, comparing cell pellets to their respective supernatants. In general, the microarrays had good images after scanning. Because each FNA sample was divided into two fractions and those fractions were hybridized together on one slide, we could directly compare the data from the cell pellet to that from the supernatant. The signals from each channel were normalized by dividing each signal by the median of all measurements from this channel. The comparison between the data from the cell pellet and that from the supernatant showed high correlation for each fine-needle aspirate sample (Table 2 and 
DISCUSSION
As an expression microarray core facility, we have determined that the best way to get good, reliable results from a microarray experiment is to start with RNA of exceptionally high quality. Isolating such RNA poses a significant problem, especially when the samples are taken directly from patients. However, this obstacle must be overcome because patient samples tell the most physiologically relevant story, as opposed to cell lines or animal models. Although there was degradation of RNA in some of the FNA samples, that might be explained by variable delay between surgical excision and ex vivo FNA sampling of tumors. Of note, there was similar quality of RNA isolated from matched cell pellet and supernatant samples.
Fine-needle aspirate samples from tumors are particularly useful because they represent a relatively pure population of tumor cells, relatively free from the contaminating normal cells that would be expected in a surgical resection. This purity is particularly useful when we consider the subtle changes that may occur at the beginning of tumorigenesis (6) . Contaminating normal cells could potentially dampen a small but important change in a tumor's gene expression pattern. In addition, obtaining fine-needle aspirates is a much safer and less invasive procedure than surgery. In fact, it is conceivable that repeated aspirates could be collected from the same tumor to monitor the progression of the disease and the tumor's response to therapy (4, 5, 15, 16 Even when we isolated the maximum possible amount of RNA, fineneedle aspirate samples did not typically yield more than 5 µg total RNA. This quantity is sufficient for microarray analysis but is not optimal for the traditional denaturing agarose gel electrophoresis that needs to be done to determine RNA quality before the microarray hybridization protocol is started. Usually 0.5-1 µg RNA needs to be loaded on a gel to visualize with UV light. This amount could conceivably be most of the RNA yield from a fine-needle aspirate sample. For such samples with low yield or any other precious samples, the model 2100 Bioanalyzer can remove the need for running a standard gel. The acceptable loading range for an RNA LabChip is 5-500 ng total RNA. This range is dramatically lower than the amount needed to determine RNA quality on a gel, leaving a much larger proportion of the sample available for experimental work.
After completing this preliminary feasibility study, we plan to hybridize additional expression microarrays with RNA isolated from additional FNA samples, combining cell pellet and supernatant, to screen for differentially expressed genes that may serve as prognostic indicators or therapeutic targets. 
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